Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)

NCT: NCT06096246 · RECRUITING

NCT IDNCT06096246
StatusRECRUITING
Start Date2024-07-26
Completion2027-12-05
SponsorBarts & The London NHS Trust (OTHER)
First posted
Last updated

Brief Summary

The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.

Frequently Asked Questions

What is Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)?

Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) is a clinical trial registered under NCT06096246. Current status: RECRUITING.

What is the status of NCT06096246?

The current status of NCT06096246 (Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)) is: RECRUITING.

When did Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) start?

Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) started on 2024-07-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑